Business Context and Reporting Period
Gossamer Bio, Inc. (GOSS) filed a Form 8-K on March 5, 2024, to announce the issuance of a press release detailing financial results for the quarter and fiscal year ended December 31, 2023. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.1), which is incorporated by reference but not detailed in the body of this 8-K form.
Material Changes
The filing does not explicitly list material changes versus the prior comparable period. It serves solely as a notification that the results for the period ended December 31, 2023, have been released.
Guidance, Outlook, and Risks
This 8-K filing does not contain specific guidance, outlook, management commentary, or risk factors. It references the attached press release for the full text of the financial results. The filing includes standard disclaimers stating that the information is not deemed "filed" under Section 18 of the Exchange Act for liability purposes.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 5, 2024) for specific revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the attached exhibit.
- Confirm the status of any outstanding debt or financing arrangements referenced in the full financial report.